Research programme: obesity therapeutics - MitoRx Therapeutics
Latest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator MitoRx Therapeutics
- Class Small molecules
- Mechanism of Action Electron transport chain complex protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 12 Sep 2024 Preclinical trials in Obesity in United Kingdom (PO), prior to September 2024 (MitoRx Therapeutics pipeline, September 2024)